-+ 0.00%
-+ 0.00%
-+ 0.00%

Valion Bio Completes 200-Liter Entolimod Production Run to Supply Ongoing Study

PUBT·11/17/2026 13:06:45
Listen to the news
Valion Bio Completes 200-Liter Entolimod Production Run to Supply Ongoing Study
  • Valion Bio today reported completion of an Entolimod production run supplying its ongoing Armed Forces Radiobiology Research Institute study.
  • The May-June 2026 run improved productivity, with drug substance meeting all predefined quality acceptance criteria.
  • Entolimod is being developed for acute radiation syndrome under the FDA’s Animal Rule, with Fast Track and Orphan Drug designations.
  • The ongoing study is fully funded by the National Institute of Allergy and Infectious Diseases through an interagency agreement.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valion Bio Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202611170805ACCESSWRNAPR_____1252411) on November 17, 2026, and is solely responsible for the information contained therein.